Status:
TERMINATED
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Lead Sponsor:
Vanderbilt University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease. However, pati...
Detailed Description
Tissue-type Plasminogen Activator (tPA) is a protein in the blood which breaks down clots and plays an important role in preventing myocardial infarction. It is produced by the endothelial cell lining...
Eligibility Criteria
Inclusion
- Age \>18 year old male and female patients
- All patients are referred for elective cardiac catheterization based on clinical indication
- Cath shows mild or moderate (\<70% stenosis) CAD that does not require mechanical intervention
Exclusion
- Severe stenosis requires intervention.
- Significant left main coronary artery disease (\>40%).
- Acute MI or acute coronary syndrome with enzyme elevation or ischemic EKG changes
- Patients with severe left ventricular dysfunction (EF\<35%)
- Prior history of myocardial infarction
- History of stroke within 3 months.
- Recent history of thrombolytic
- History of coronary intervention within previous 6 months.
- Patients with history of coronary spasm
- Patients with congestive heart failure (class III and IV).
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00868855
Start Date
December 1 2003
End Date
December 1 2010
Last Update
December 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232